Supremacy in scientific knowledge is a crucial factor in our struggle to advance medicine and enhance survival, but, without the discoveries of clinical and basic research, our learning and, thus, technology cannot continue to advance. To assure this scientific supremacy, it is imperative that we assemble the best ingredients to investigate/advance and disseminate knowledge.
Is there possibly an overestimation of the effectiveness and an underestimation of the dangers of medical interventions, especially when doing so may lead to the overuse of medical therapies?
Attempting to answer this question, David Jones, in "Broken Hearts: the tangled history of cardiac care", 1 whilst exploring the history of cardiology and cardiac surgery, probes the ambiguities and inconsistencies in medical decision making. Based on extensive reviews of the medical literature and archives, this historical perspective on medical decision making and risk highlights personal, professional and community outcomes.
His view is that: "Doctors generate better knowledge of efficacy than of risk, and that this skews decision making. They design treatments to do something specific and design studies to see if those treatments achieved those outcomes; and so accumulate lots of data on whether treatments produce the desired effects". He continues by saying, "Capturing good knowledge of side effects, especially the unanticipated ones that are so common, is both less interesting and more difficult. Whenever doctors have a more thorough knowledge of the possible benefits of a treatment than they do of its potential risks, patients and doctors will lean towards intervention."
The incentive to succeed is not without financial incentive. Industry has to be commended for its continuation of encouragement and support in spite of the unpredictability of success.
Dalcetrapib, sponsored by "Roche", a cholesteryl ester transfer protein (CTEP) inhibitor to be used in stable coronary heart disease (CHD) following an acute coronary syndrome, failed to meet the primary endpoint of lowering cardiovascular risk beyond the level achieved with intensive statin treatment, in dal-OUTCOMES Phase III trial, and was halted following results of second interim analysis. Thus, in May 2012, was announced as a failure. 2 The cost of development write-off attributed to the Dalcetrapib was: CHF 242 million ($259.3 million) in charges, consisting of CHF 130 million ($139.3 million) for restructuring costs (provisions for the remaining trial costs and write-offs of inventories and property, plant and equipment) and CHF 112 million ($120 million) for the write-off of previously acquired intangible assets. Thus, cost in the climate of financial restraint is an important concession.
I have the pleasure of introducing manuscripts starting with "DOES?" The first is a review article by Philip De Somer, "Does contemporary oxygenator design influence haemolysis?" This is important for us to continue to review our practice in the light of an event that may not have even been thought of during the design and manufacture period, but has subsequently come to light and now may or may not still be playing an important role.
Leanne Harling and associates from Imperial College London analyse redo off-pump coronary artery bypass grafting (CABG) and mortality by meta-analysis. Metaanalysis is an excellent mode to review current published literature in the absence of a simple randomised trial, which, currently, is mostly impractical. Finally, it answers the question, "DOES?" Starck gives us initial results of an optimised perfusion system, followed by Buccisano who confirms mini extracorporeal circulation minimises coagulation abnormalities and ameliorates pulmonary outcome. Again, we look at advances in technology that make a real clinical impact, not just positive, but also negative impact.
Editorial Papadoupoulos looks at the effect of normovolemic modified ultrafiltration and evaluates inflammatory mediators, endotoxins and terminal complement complexes as well as their correlation with clinical outcomes. In the high-risk cardiac surgical group of patients, nowadays, co-morbidities are increasing worldwide and we need these evaluation advancements for us to be able to continue to deliver the high success rates.
Attempts to conserve blood in ascending and aortic arch surgery is presented by Chu et al. Critical to achieving reduction in blood usage in cardiac surgery.
Lindstedt, Joshi, Assadi, Antonitsis, Sikora and Gobolos tackle different topics, ranging from delivery pressure in cardioplegia solutions in paediatrics to the need of extracorporeal membrane oxygenation (ECMO) with a sixteen-year experience and perfusion scanning.
It is important to remember that we are in an era where it is extremely important for us not just to look at the benefit, but also the potential risks and then make a judged decision for recommendation.
I am also very pleased to inform you that by the time you are reading this Editorial, this will be the first year in the journal's history that we have received over one hundred manuscripts (104 to be precise) for consideration in the first five months of the year.
